UCA1（urothelial carcinoma antigen 1）为自主研发的1个尿路上皮癌基因.应用 实时荧光定量PCR检测UCA1 mRNA在2种膀胱癌细胞系、11种非膀胱癌细胞系、18对膀胱 癌组织和配对癌旁正常膀胱组织中的表达，对表达差异进行统计学分析.结果显示， UCA1在2种膀胱癌细胞系中显著高表达，而在其他11种非膀胱癌细胞系中表达水平很低 或者不表达，二者表达差异达14~24 812倍，差异有统计学意义（P<0.001）；在18例膀 胱癌组织中,UCA1的平均表达水平是癌旁正常膀胱组织的12.4倍，表达差异有统计学意 义（P<0.001）. 实时荧光定量PCR使UCA1在膀胱癌细胞系及组织中的特异性高表达得以 量化.实验结果明确了UCA1作为潜在的肿瘤标记物在膀胱癌临床诊断中的意义，为定量 检测尿液UCA1表达并确定诊断膀胱癌的参考值打下基础.
Abstract
We have previously isolated and indentified a novel gene, referred to as urothelial carcinoma antigen 1 (UCA1). Real-time PCR was used to quantitatively detect UCA1 mRNA in 2 types of bladder cancer cell lines, 11 non-bladder cancer cell lines, 18 cases of bladder cancer tissues and paired adjacent normal bladder urothelial tissues. The expression difference was statistically analyzed. The results showed that UCA1 expression in the bladder cancer cell lines was significantly increased compared with that in the non-bladder cancer cell lines by 14~24 812 folds (P<0.001). The average UCA1 level was 12.4 fold greater over-expressed in the bladder cancer tissues than that in adjacent normal bladder tissues (P<0.001). The high expression of UCA1 in both bladder cancer cell lines and tissues were quantified by real time PCR, based on which quantitative detection of UCA1 in urine samples will be fulfilled and the reference value range of UCA1 for diagnosis of bladder cancer will be obtained. The results clearly imply UCA1 is a potential tumor biomarker in the diagnosis of bladder cancer and provide a reliable experimental basis for further research.
关键词
尿路上皮癌胚抗原1 /
膀胱癌 /
肿瘤分子标记物 /
实时聚合酶链反应
{{custom_keyword}} /
Key words
urothelial carcinoma antigen 1 /
bladder cancert /
umor biomarker /
Real-time PCR
{{custom_keyword}} /
中图分类号：
R737.14
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Zhang W, Xiang Y B, Liu Z W, et al. Trends analysis of common urologic neoplasm incidence of elderly people in Shanghai, 1973-1999 [J]. Ai Zheng(Article in Chenese), 2004,23(5):555-558
[2] Dey P. Urinary markers of bladder carcinoma [J]. Clin Chim Acta, 2004,340(1-2):57-65
[3] Glas A S, Roos D, Deutekom M,et al. Tumor markers in the diagnosis of primary bladder cancer[J]. J Urol, 2003,169(6):1975-1982
[4] Wang X S, Zhang Z, Wang H C, et al. Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma[J]. Clin Cancer Res, 2006, 12(16): 4851-4858
[5]Proctor I, Stoeber K,Williams G H. Biomarkers in bladder cancer[J]. Histopathology,2010,57(1): 1-13
[6] Mitra A P, Cote RJ. Molecular screening for bladder cancer: progress and potential [J]. Nat Rev Urol,2010,7(1):11-20
[7] Christoph F, Muller M, Schostak M, et al. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction [J]. Urology, 2004, 64(1):157-161
[8] Melissourgos N, Kastrinakis N G, Davilas I, et al. Detection of human telomerase reverse transcriptase mRNA in urine of patients with bladder cancer: evaluation of an emerging tumor marker [J]. Urology, 2003, 62(2):362-367
[9]Schrader A J,Lauber J, Lechner O, et al. Application of real-time reverse transcriptase-polymerase chain reaction in urology oncology [J]. J Urol, 2003 169(5):1858-1864
[10] Shen X, Hu L, Xia L, et al. The detection of circulating tumor cells of breast cancer patients by using multimarker (Survivin, hTERT and hMAM) quantitative real-time PCR [J]. Clin Biochem, 2009,42(3):194-200
[11] de Kok J B, Verhaegh G W, Roelofs R W, et al. DD3(PCA3),a very sensitive and specific marker to detect prostate tumors [J]. Cancer Res, 2002, 62(9):2695-2698
[12] Xie X Y, Yang X, Zhang J H, et al. Analysis of hTERT expression in exfoliated cells from patients with bladder transitional cell carcinomas using SYBR green real-time fluorescence quantitative PCR [J]. Ann Clin Biochem, 2007 , 44(6) :523-528
[13] Guo B, Luo C, Xun C, et al. Quantitative detection of cytokeratin 20 mRNA in urine samples as diagnostic tools for bladder cancer by real-time PCR [J]. Exp Oncol, 2009 , 31(1) : 43-47
[14] Szarvas T, Becker M, vom Dorp F, et al. Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer [J]. Cancer Sci, 2010 ,101(5):1300-1308
[15] Miyake M, Sugano K, Sugino H, et al. Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer [J]. Cancer Sci, 2010 ,101(1):250-258
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
国家自然科学基金青年科学基金项目(No.30801325)
{{custom_fund}}
PDF(323 KB)
